Please note, this OEL/ADE monograph also applies to neomycin sulfate (CAS RN 1405-10-3), neomycin B/framycetin (CAS RN 119-04-0) and neomycin B sulfate (28002-70-2). Neomycin oral therapy is indicated for hepatic encephalopathy (brain disorder due to liver dysfunction), skin infection and bowel surgery preparation. Neomycin sulfate is an aminoglycoside antibiotic that exerts its bactericidal effect by inhibiting protein synthesis in susceptible bacterial cells. It is effective against gramnegative bacilli and some strains of gram-positive microorganisms, but ineffective against anaerobic bowel flora.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Neomycin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.